Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
24.00
-0.50 (-2.04%)
At close: Mar 13, 2026, 4:00 PM EDT
24.04
+0.04 (0.17%)
After-hours: Mar 13, 2026, 4:10 PM EDT
Zenas BioPharma Employees
Zenas BioPharma had 130 employees as of December 31, 2024.
Employees
130
Change
n/a
Growth
n/a
Revenue / Employee
$115,385
Profits / Employee
-$1,460,762
Market Cap
1.29B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 130 | 23 | 21.50% |
| Sep 30, 2024 | 115 | 31 | 36.90% |
| Jun 30, 2024 | 114 | 30 | 35.71% |
| Mar 31, 2024 | 107 | - | - |
| Sep 30, 2023 | 84 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Immatics | 645 |
| Ardelyx | 489 |
| Monte Rosa Therapeutics | 147 |
| MoonLake Immunotherapeutics | 130 |
| Rapport Therapeutics | 84 |
| Taysha Gene Therapies | 73 |
| Savara | 59 |
| AtaiBeckley | 54 |
ZBIO News
- 21 days ago - Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026 - GlobeNewsWire
- 5 weeks ago - Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 7 weeks ago - These 20 stocks are strong choices for momentum investors - Market Watch
- 2 months ago - Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Zenas BioPharma, Inc. (ZBIO) Discusses Positive Phase 3 INDIGO Trial Results for Obexelimab in IgG4-Related Disease Transcript - Seeking Alpha
- 2 months ago - Why Zenas BioPharma's Selloff Was Structurally Inevitable - Benzinga
- 2 months ago - Zenas: Maintaining 'Strong Buy' As Cross-Trial Comparison Of Obexelimab Should Not Be A Factor - Seeking Alpha